reports
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Eje...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sot...
- Jonathan Moreland
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
JBLU JETBLUE AIRWAYS CORPORATION
GBCI GLACIER BANCORP INC.
ASA ASA
TZOO TRAVELZOO
RLMD RELMADA THERAPEUTICS
NSC NORFOLK SOUTHERN CORPORATION
GCBC GREENE COUNTY BANCORP INC.
CSBR CHAMPIONS ONCOLOGY
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
CSBB C S B BANCORP OHIO
AVO MISSION PRODUCE
TDUP THREDUP INC.
NVCT NUVECTIS PHARMA INC
BPRN BANK OF PRINCETON
GTE GRAN TIERRA ENERGY INC.
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results a...
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas,...
Standard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Reports Third Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025. Recent Highlights: Third quarter 2025 total combined company revenue of $46.2 million; Revenue from continuing operations of $19.6 millionImplemented restructuring plan expected to deliver over $40 million in annualized cost savings; On track to achieve positive adjusted EBITDA target in 2026$217.0 million in ...
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient...
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming medical meetings. Two studies will be presented at the American Heart Association’s (AHA) Scientific Sessions 2025, b...
Fiserv Inc: 1 director
A director at Fiserv Inc bought 10,000 shares at 65.180USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Capital Southwest Announces Financial Results for Second Fiscal Quarte...
Capital Southwest Announces Financial Results for Second Fiscal Quarter Ended September 30, 2025 DALLAS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced its financial results for the second fiscal quarter ended September 30, 2025. Second Quarter Fiscal Year 2026 Financial Highlights Total Investment Portfolio: $1.9 billion Credi...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
EVEREST RE GROUP LTD.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCN FTI CONSULTING INC.
CRMD CORMEDIX INC.
CNS COHEN & STEERS INC.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ANGO ANGIODYNAMICS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
QRHC QUEST RESOURCE HOLDING
QTA QUATERRA RESOURCES INC.
ATRO ASTRONICS CORPORATION
NSC NORFOLK SOUTHERN CORPORATION
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
UTG REAVES UTILITY INCOME FUND
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
BX THE BLACKSTONE GROUP L.P.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
WGO WINNEBAGO INDUSTRIES INC.
NWFL NORWOOD FINANCIAL CORP.
OBNK ORIGIN BANCORP
CHMG CHEMUNG FINANCIAL CORP.
AVTR AVANTOR
RYES INC.
VRDN PATRIOT MINEFINDERS INC.
SMMT VIRIDIAN THERAPEUTICS INC
INTA SUMMIT THERAPEUTICS INC
NVCT INTAPP INC
EBC NUVECTIS PHARMA INC
NMRA EASTERN BANKSHARES INC
EP NEUMORA THERAPEUTICS INC
CLS EMPIRE PETROLEUM CORP
GF CELESTICA INC.
ECF THE NEW GERMANY FUND
NUGN INC.
XFOR ELLSWORTH FUND LTD
STBA LIVENTO GROUP
KITT INC.
X4 PHARMACEUTICALS INC.
S&T BANCORP
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
EVEREST RE GROUP LTD.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCN FTI CONSULTING INC.
CRMD CORMEDIX INC.
CNS COHEN & STEERS INC.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ANGO ANGIODYNAMICS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
QRHC QUEST RESOURCE HOLDING
QTA QUATERRA RESOURCES INC.
ATRO ASTRONICS CORPORATION
NSC NORFOLK SOUTHERN CORPORATION
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
UTG REAVES UTILITY INCOME FUND
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
BX THE BLACKSTONE GROUP L.P.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
WGO WINNEBAGO INDUSTRIES INC.
NWFL NORWOOD FINANCIAL CORP.
OBNK ORIGIN BANCORP
CHMG CHEMUNG FINANCIAL CORP.
AVTR AVANTOR
RYES INC.
VRDN PATRIOT MINEFINDERS INC.
SMMT VIRIDIAN THERAPEUTICS INC
INTA SUMMIT THERAPEUTICS INC
NVCT INTAPP INC
EBC NUVECTIS PHARMA INC
NMRA EASTERN BANKSHARES INC
EP NEUMORA THERAPEUTICS INC
CLS EMPIRE PETROLEUM CORP
GF CELESTICA INC.
ECF THE NEW GERMANY FUND
NUGN INC.
XFOR ELLSWORTH FUND LTD
STBA LIVENTO GROUP
KITT INC.
X4 PHARMACEUTICALS INC.
S&T BANCORP
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
RHI ROBERT HALF INTERNATIONAL INC.
EVEREST RE GROUP LTD.
FMNB FARMERS NATIONAL BANC CORP.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ASA ASA
GAM GENERAL AMERICAN INVESTORS CO. INC.
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
CHMG CHEMUNG FINANCIAL CORP.
CGEM CULLINAN ONCOLOGY INC
CLS CELESTICA INC.
GF THE NEW GERMANY FUND
ECF INC.
STBA ELLSWORTH FUND LTD
S&T BANCORP
INC.
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results...
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s webs...
- Jonathan Moreland
Greene County Bancorp, Inc. Announces Cash Dividend
Greene County Bancorp, Inc. Announces Cash Dividend CATSKILL, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (NASDAQ-GCBC) today announced that its Board of Directors has approved a quarterly cash dividend of $0.10 per share on the Company’s common stock. The dividend reflects an annual cash dividend rate of $0.40 per share, which is the same rate as the dividend declared during the previous quarter. The cash dividend for the quarter ended September 30, 2025, will be paid to shareholders of record as of November 14, 2025, and is expected to be paid on November 28, 20...
Greene County Bancorp, Inc. Reports Net Income of $8.9 Million for the...
Greene County Bancorp, Inc. Reports Net Income of $8.9 Million for the Three Months Ended September 30, 2025, and Finalized Expansion Plans into Saratoga County CATSKILL, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for the Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the three months ended September 30, 2025, which is the first quarter of the Company’s fiscal year ending June 30, 2026. Net income for the three months ended September 30, 2025, was $8.9 millio...
Standard BioTools to Announce Third Quarter Financial Results on Novem...
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable a...
Capital Southwest Announces Preliminary Estimate of Second Quarter 202...
Capital Southwest Announces Preliminary Estimate of Second Quarter 2026 Operating Results and Earnings Release and Conference Call Schedule DALLAS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce its preliminary operating results for the second quarter of its 2026 fiscal year (quarter ended September 30, 2025) and its second quarter 2026 earnings r...
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabet...
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit – Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These data follow the from the Phase 2b PROGRESS ...
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy G...
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and policy efforts to better meet the needs of Americans suffering from chronic pain. The perspectiv...
Lexicon Pharmaceuticals Announces Update on Submission of Additional D...
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting now expected during the fourth quarter THE WOODLANDS, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced an update to the previous s...
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic...
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1-inhibitor, pilavapa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.